Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Why XOM is close to an ideal option trading candidate

XOM has a hugely active options series, trades in both monthly and weekly expiration series and has bid / ask spreads that are just a few pennies wide. One of the most interesting aspects of options is the myriad opportunities presented for high probability trades for thos...
J.W. Jones | February 6, 2013 |

Alpine Immune Shares Soar 160% on Global Option and License Agreement with AbbVie

Shares of Alpine Immune Sciences set a new 52-week high after the company reported that it entered into an exclusive worldwide option and license agreement with AbbVie Inc. to develop and commercialize ALPN-101. Clinical-stage immunotherapy company Alpine Immune S...
Streetwise Reports | June 19, 2020 |

Why You May Want to Avoid Buying Options This Week

If you do not understand implied volatility and you are buying put or call options or some combination, you have been warned! The market continues to move very fast, has large swings, and one would think that makes it an excellent time to buy options for huge gains, r...
Chris Vermeulen | March 10, 2020 |

Leap Therapeutics Lunges Forward on $132M Licensing Deal and $27M Equity Raise

Shares of Leap Therapeutics jumped 60% after the company reported that it signed an exclusive option and license agreement for its immuno-oncology drug DKN-01 with BeiGene in the Asia Pacific region excluding Japan. The firm also secured an additional $27 million in equity fin...
Streetwise Reports | January 6, 2020 |

Why The Coming Silver Rally Might Be The Greatest

In the last one hundred years there have been some great silver rallies. Some have been greater than others though. The economic conditions underlying the different silver rallies were not all the same. Obviously those that occurred during conditions most conducive to silv...
Hubert Moolman | July 23, 2019 |

Exclusive CEO Interview Karim Rayani, Marvel Discovery Corp.

Earlier this month copper & nickel hit all-time highs and gold came within 1% of an ATH. increased its 3 & 6 month gold targets to & . Still, many metals/mining juniors are well below their 52-week highs. That could change at any time. In commodity bull markets, investors...
Peter Epstein | March 18, 2022 |

Biotech's Topline Breast Cancer Data Impresses

Biotech's Topline Phase 3 HER2-Positive Breast Cancer Data 'Impresses' The results and commercial potential of the therapeutic are discussed in an H.C. Wainwright & Co. report. In an Oct. 22 research note, H.C. Wainwright & Co. analyst Andrew Fein reported that t...
Streetwise Reports | October 24, 2019 |

17 best payday loans online: Quick cash and fast approval this Christmas

If you face a financial emergency, traditional loans may not be a viable option if you have bad credit. So what can you do when you need quick cash – especially close if you need cash for Christmas gifts during the festive season? The best online payday loans are an a...
Dominic Castleberry | December 11, 2023 |

Analyst: Biopharma, Now Stronger Than Ever, Is an Ideal Takeout Target

An argument is made in a ROTH Capital Partners report for a potential imminent deal involving this drug maker. In an April 15 research note, ROTH Capital Partners analyst Yasmeen Rahimi reviewed the reasons why Galmed Pharmaceuticals Ltd. (GLMD:NASDAQ) is "high on the...
Streetwise Reports | April 18, 2019 |

PlantX Life: Must-see Investor Update with CEO Julia Frank

(Click image to play video) They truly have become “the digital face of the plant-based community” and they’re called Plant-X Life Inc. (VEGA) ( CSE.VEGA , Forum ) – a one-stop-shop and distribution company with a fast-gr...
Dave Jackson | February 22, 2021 |
1 2 3 4 5 6 7 8 9 10 ...